ct-0508
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 2, 2021 (NCT04660929)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma · Phase 1
- Bile Duct Neoplasms · Phase 1
- Biliary Tract Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Ductal · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Small Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Genes, erbB-2 · Phase 1
- Head and Neck Neoplasms · Phase 1
- Inflammatory Breast Neoplasms · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Stomach Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, passive
ERBB2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04660929 | Phase 1 | Feb 2, 2021 | Carisma Therapeutics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Carisma Therapeutics | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1